Hepatorenal Syndrome Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 | Becton Dickinson and Company, BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, ESP Pharma I

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10414&type=smp

Rising Incidences Of Liver Damage And Cirrhosis Fueling Growth In The Hepatorenal Syndrome Treatment Market
An increase in the incidences of patients with liver damage or cirrhosis is expected to propel the growth of the hepatorenal syndrome treatment market going forward. Cirrhosis is a severe form of liver disease in which scar tissue permanently replaces good liver tissue. Hepatorenal syndrome treatment aims to retain the patient's kidney function while alleviating symptoms and adverse effects of the disorder. These strategies may help to improve overall health and make you a better candidate for liver transplant surgery. For instance, in September 2022, according to a Fact Sheet published by the Centers for Disease Control and Prevention, a US-based Government agency, the number of adults with diagnosed liver disease in the US was 4.5 million. Moreover, according to Medscape, a website providing access to medical information, states ALD-related fatalities increased by 17.6% between 2019 and 2021, whereas NAFLD-related deaths climbed by 14.5%. Therefore, the increase in the incidences of patients with liver damage or cirrhosis is driving the growth of the hepatorenal syndrome treatment market.

Increasing Emphasis On Research And Development Driving Advances In Hepatorenal Syndrome Treatment
Increasing research and development activities for hepatorenal syndrome treatment is a key trend gaining popularity in the hepatorenal syndrome treatment market. Companies operating in the hepatorenal syndrome treatment market are now focusing more on research and development to sustain their position in the market. For instance, in September 2022, Mallinckrodt Pharmaceuticals, an Ireland-based company specializing in developing, manufacturing, and distributing specialty products and therapies, announced the FDA approval for Terlivaz for an injection that helps adults with hepatorenal syndrome's kidney function. The Phase 3 CONFIRM trial, the largest-ever prospective research (n=300) done to evaluate the safety and efficacy of terlipressin in patients with HRS type 1 (HRS-1) in the U.S. and Canada, was a significant factor in the FDA's approval. Verified HRS Reversal, measured as an improvement in renal function, avoiding the need for dialysis, and short-term survival, was achieved by the CONFIRM trial's primary endpoint (p=0.012).

The hepatorenal syndrome treatment market covered in this report is segmented -

1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=10414&type=discount

Major companies operating in the hepatorenal syndrome treatment market report are Becton Dickinson and Company, BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, ESP Pharma Inc., PharmaIN Corporation, Baxter International Inc., La Jolla Pharmaceutical Company, Noorik Biopharmaceuticals AG, Novartis AG, Zydus Lifesciences limited, Mount Sinai Health System Inc., NYU Langone Health, Max Healthcare Institute Limited, 3A Composites, Ocelot Bio Inc., New Medicon Pharma Lab Private Limited, Allergan plc, Arrowhead Pharmaceuticals, Stealth BioTherapeutics Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Conatus Pharmaceuticals Inc., Catalyst Pharmaceuticals Inc., Bayer AG, Gilead Sciences Inc.

Contents of the report:
1. Executive Summary
2. Hepatorenal Syndrome Treatment Market Report Structure
3. Hepatorenal Syndrome Treatment Market Trends And Strategies
4. Hepatorenal Syndrome Treatment Market - Macro Economic Scenario
5. Hepatorenal Syndrome Treatment Market Size And Growth
…..
27. Hepatorenal Syndrome Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.